The Lancet has published two separate corrections for recent articles on Parkinson's disease and Alzheimer's disease. The corrections apply to articles originally published in the journal earlier this year and were made online as of July 2, 2026.
One correction addresses a phase 2b trial of intravenous prasinezumab for early-stage Parkinson's disease. The appendix of that study has been corrected, though the nature of the error was not specified in the notice.
The other correction involves a comprehensive Alzheimer's disease Seminar. It notes two fixes: a mislabeled brain region in figure 2C and an adjustment to the obesity risk factor contribution, which should have been stated as 1% rather than a previously reported figure.
These corrections highlight the ongoing process of scientific self-correction but may raise questions about data integrity for readers. Neither correction indicated whether the errors affected the studies' primary conclusions or statistical significance.
The journal did not provide additional context on how the errors were discovered or whether they originated from author oversight or editorial processes. Both corrections were applied only to online versions.